Ionis Pharmaceuticals
Search results
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions.
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Get the latest Alnylam Pharmaceuticals, Inc. (ALNY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
May 13, 2024 · Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, is translating the promise of RNAi research into a new class of powerful therapies.
Alnylam Pharmaceuticals | 195,499 followers on LinkedIn. Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach. | To those who...
Jul 29, 2021 · About Alnylam Pharmaceuticals. Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize ...
Visit our social channels to learn more about the innovative work we are doing at Alnylam.
